Vramath Financial Services Private Limited has disclosed a significant acquisition in lotus eye hospital through open market transactions, as per regulatory filing dated February 05, 2025. The acquisition represents a substantial increase in the company's shareholding and triggers disclosure requirements under SEBI regulations.

Acquisition Details

The transaction involves the acquisition of 20,84,835 equity shares, representing 10.02% of the total share capital of Lotus Eye Hospital and Institute Limited. The acquisition was completed through open market purchases on February 02, 2025.

Shareholding Pattern Changes

The acquisition significantly altered Vramath Financial Services' shareholding position in the target company. Prior to this transaction, the acquirer along with persons acting in concert held a modest stake of 1.73%.

Persons Acting in Concert

The disclosure identifies several entities and individuals acting in concert with Vramath Financial Services Private Limited:

• Vramath Investment Consultancy Private Limited
• PL.M.Palaniappan
• PL. Jayalakshmi
• PL.M.Palaniappan HUF
• PL. Ram Meyyappan

The acquirer has confirmed that it does not belong to the promoter or promoter group of the target company.

Regulatory Compliance

The disclosure was filed under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, which mandates disclosure when shareholding crosses specific thresholds. The target company's shares are listed on both BSE Limited and National Stock Exchange of India Limited.

The total equity share capital of Lotus Eye Hospital and Institute Limited remains unchanged at 2,07,96,330 shares before and after the acquisition. The filing was signed by Jayalakshmi Palaniappan, Director of Vramath Financial Services Private Limited (DIN: 03524597), from Coimbatore on February 05, 2025.

Lotus eye hospital And Institute Limited has announced that its Board of Directors will convene on February 11, 2026, to review the company's quarterly financial performance. The meeting has been scheduled in accordance with regulatory requirements under SEBI (LODR) Regulations 2015.

Board Meeting Details

The primary agenda for the board meeting includes consideration of the unaudited standalone financial results for the quarter and year ended December 31st, 2025. The company has formally notified both major stock exchanges about this scheduled meeting.

Trading Window Restrictions

In compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's Code of Conduct for Insiders, Lotus Eye Hospital has implemented trading window restrictions. The trading window will remain closed until the financial results are announced and will reopen from February 13, 2026 onwards.

Stock Exchange Communication

The company has sent formal intimation letters to both BSE Limited and National Stock Exchange of India Limited regarding the upcoming board meeting. The communication was signed by M Achuth Menon, Company Secretary & Compliance Officer, on January 30th, 2026.

The announcement follows standard corporate governance practices and ensures transparency in financial reporting. Investors and stakeholders will receive the Q3FY26 financial results following the board meeting scheduled for February 11, 2026.